Kimberly Maersk-Moller Sells 4,106 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total value of $17,732.40.

MiMedx Group Stock Performance

MDXG opened at $7.92 on Friday. The firm has a market cap of $1.17 billion, a P/E ratio of 14.40 and a beta of 1.97. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The business’s fifty day moving average is $8.45 and its 200-day moving average is $7.82.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Sell-side analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

Institutional Trading of MiMedx Group

Several large investors have recently bought and sold shares of MDXG. IMG Wealth Management Inc. acquired a new stake in MiMedx Group in the fourth quarter valued at about $28,000. Virtus Fund Advisers LLC bought a new position in MiMedx Group in the fourth quarter valued at about $35,000. Van ECK Associates Corp bought a new position in MiMedx Group in the fourth quarter valued at about $40,000. Point72 DIFC Ltd raised its position in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.